Literature DB >> 33861144

SERCA2a-phospholamban interaction monitored by an interposed circularly permutated green fluorescent protein.

Maren E Arnold1,2, Wolfgang R Dostmann3, Jody Martin4, Michael J Previs1, Bradley Palmer1, Martin LeWinter1, Markus Meyer5.   

Abstract

The interaction of phospholamban (PLB) and the sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) is a key regulator of cardiac contractility and a therapeutic target in heart failure (HF). PLB-mediated increases in SERCA2a activity improve cardiac function and HF. Clinically, this mechanism can only be exploited by a general activation of the proteinkinase A (PKA), which is associated with side effects and adverse clinical outcomes. A selective interference of the PLB-SERCA2a interaction is desirable but will require novel tools that allow for an integrated assessment of this interaction under both physiological and pathophysiological conditions. A circularly permutated green fluorescent protein (cpGFP) was interposed between SERCA2a and PLB to result into a single SERCA2a-cpGFP-PLB recombinant protein (SGP). Expression, phosphorylation, fluorescence, and function of SGP were evaluated. Expression of SGP-cDNA results in a functional recombinant protein at the predicted molecular weight. The PLB domain of SGP retains its ability to polymerize and can be phosphorylated by PKA activation. This increases the fluorescent yield of SGP by between 10% and 165% depending on cell line and conditions. In conclusion, a single recombinant fusion protein that combines SERCA2a, a circularly permutated green fluorescent protein, and PLB can be expressed in cells and can be phosphorylated at the PLB domain that markedly increases the fluorescence yield. SGP is a novel cellular SERCA2a-PLB interaction monitor.NEW & NOTEWORTHY This study describes the design and characterization of a novel biosensor that can visualize the interaction of SERCA2a and phospholamban (PLB). The biosensor combines SERCA2a, a circularly permutated green fluorescent protein, and PLB into one recombinant protein (SGP). Proteinkinase A activation results in phosphorylation of the PLB domain and is associated with a marked increase in the fluorescence yield to allow for real-time monitoring of the SERCA2a and PLB interaction in cells.

Entities:  

Keywords:  SERCA2a; calcium; phospholamban; sarcoplasmic reticulum

Mesh:

Substances:

Year:  2021        PMID: 33861144      PMCID: PMC8289358          DOI: 10.1152/ajpheart.00858.2020

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   5.125


  49 in total

1.  Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility.

Authors:  H He; M Meyer; J L Martin; P M McDonough; P Ho; X Lou; W Y Lew; R Hilal-Dandan; W H Dillmann
Journal:  Circulation       Date:  1999-08-31       Impact factor: 29.690

2.  Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter.

Authors:  K Eizema; H Fechner; K Bezstarosti; S Schneider-Rasp; A van der Laarse; H Wang; H P Schultheiss; W C Poller; J M Lamers
Journal:  Circulation       Date:  2000-05-09       Impact factor: 29.690

3.  MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.

Authors:  Thomas S O'Leary; Julia Snyder; Sakthivel Sadayappan; Sharlene M Day; Michael J Previs
Journal:  J Mol Cell Cardiol       Date:  2018-12-11       Impact factor: 5.000

Review 4.  Analysis of CaM-kinase signaling in cells.

Authors:  Gary A Wayman; Hiroshi Tokumitsu; Monika A Davare; Thomas R Soderling
Journal:  Cell Calcium       Date:  2011-04-29       Impact factor: 6.817

5.  Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.

Authors:  Yoshiaki Kawase; Hung Q Ly; Fabrice Prunier; Djamel Lebeche; Yanfen Shi; Hongwei Jin; Lahouaria Hadri; Ryuichi Yoneyama; Kozo Hoshino; Yoshiaki Takewa; Susumu Sakata; Richard Peluso; Krisztina Zsebo; Judith K Gwathmey; Jean-Claude Tardif; Jean-François Tanguay; Roger J Hajjar
Journal:  J Am Coll Cardiol       Date:  2008-03-18       Impact factor: 24.094

6.  Differential patterning of cGMP in vascular smooth muscle cells revealed by single GFP-linked biosensors.

Authors:  Lydia W M Nausch; Jonathan Ledoux; Adrian D Bonev; Mark T Nelson; Wolfgang R Dostmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-28       Impact factor: 11.205

7.  Self-association accompanies inhibition of Ca-ATPase by thapsigargin.

Authors:  J V Mersol; H Kutchai; J E Mahaney; D D Thomas
Journal:  Biophys J       Date:  1995-01       Impact factor: 4.033

8.  Förster transfer recovery reveals that phospholamban exchanges slowly from pentamers but rapidly from the SERCA regulatory complex.

Authors:  Seth L Robia; Kenneth S Campbell; Eileen M Kelly; Zhanjia Hou; Deborah L Winters; David D Thomas
Journal:  Circ Res       Date:  2007-11-01       Impact factor: 17.367

9.  Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.

Authors:  Kobra Haghighi; Fotis Kolokathis; Luke Pater; Roy A Lynch; Michio Asahi; Anthony O Gramolini; Guo-Chang Fan; Dimitris Tsiapras; Harvey S Hahn; Stamatis Adamopoulos; Stephen B Liggett; Gerald W Dorn; David H MacLennan; Dimitrios T Kremastinos; Evangelia G Kranias
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

10.  Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.

Authors:  Barry Greenberg; Javed Butler; G Michael Felker; Piotr Ponikowski; Adriaan A Voors; Akshay S Desai; Denise Barnard; Alain Bouchard; Brian Jaski; Alexander R Lyon; Janice M Pogoda; Jeffrey J Rudy; Krisztina M Zsebo
Journal:  Lancet       Date:  2016-01-21       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.